Citius Pharmaceuticals (CTXR) Return on Capital Employed (2011 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Return on Capital Employed came in at 71.75% in Q1 2026, down 1139.0% YoY from 6.91% in Q1 2025, and down 86.44% on a QoQ basis from 38.48% in Q4 2025.
Citius Pharmaceuticals (CTXR) Return on Capital Employed (2011 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 16 years of Return on Capital Employed data on file, last reported at 71.75% in Q1 2026.
- Quarterly Return on Capital Employed fell 1139.0% year-over-year to 71.75% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 71.75% (down 1139.0% YoY) and the FY2025 annual result came in at 48.84%, up 767.0% from the prior year.
- Return on Capital Employed retreated to 71.75% in Q1 2026, from 38.48% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 21.8% in Q1 2022 to a low of 71.75% in Q1 2026.
- A 5-year average of 42.93% and a median of 40.9% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed plunged 2282 bps — and 2025, when it surged 1931 bps.
- Tracing CTXR's Return on Capital Employed over 5 years: stood at 28.9% in 2022, then slumped by 41 bps to 40.9% in 2023, then tumbled by 41 bps to 57.8% in 2024, then jumped by 33 bps to 38.48% in 2025, then sank by 86 bps to 71.75% in 2026.
- The last three Return on Capital Employed figures came in at 71.75% (Q1 2026), 38.48% (Q4 2025), and 45.65% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 7.88% |
| 10 | Citius Pharmaceuticals | 15.86 Mn | 15.86 Mn | 1.00 Mn | -71.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -71.75% |
| Dec 31, 2025 | -38.48% |
| Sep 30, 2025 | -45.65% |
| Jun 30, 2025 | -56.56% |
| Mar 31, 2025 | -60.36% |
| Dec 31, 2024 | -57.80% |
| Sep 30, 2024 | -59.10% |
| Jun 30, 2024 | -45.76% |
| Mar 31, 2024 | -43.51% |
| Dec 31, 2023 | -40.90% |
| Sep 30, 2023 | -36.29% |
| Jun 30, 2023 | -33.64% |
| Mar 31, 2023 | -33.81% |
| Dec 31, 2022 | -28.90% |
| Sep 30, 2022 | -29.58% |
| Jun 30, 2022 | -25.90% |
| Mar 31, 2022 | -21.80% |
| Dec 31, 2021 | -18.57% |
| Sep 30, 2021 | -16.75% |
| Jun 30, 2021 | -16.40% |